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Abstract
Background: Current influenza vaccines based on the hemagglutinin protein are strain specific and do not provide good
protection against drifted viruses or emergence of new pandemic strains. An influenza vaccine that can confer cross-
protection against antigenically different influenza A strains is highly desirable for improving public health.
Methodology/Principal Findings: To develop a cross protective vaccine, we generated influenza virus-like particles
containing the highly conserved M2 protein in a membrane-anchored form (M2 VLPs), and investigated their
immunogenicity and breadth of cross protection. Immunization of mice with M2 VLPs induced anti-M2 antibodies binding
to virions of various strains, M2 specific T cell responses, and conferred long-lasting cross protection against heterologous
and heterosubtypic influenza viruses. M2 immune sera were found to play an important role in providing cross protection
against heterosubtypic virus and an antigenically distinct 2009 pandemic H1N1 virus, and depletion of dendritic and
macrophage cells abolished this cross protection, providing new insight into cross-protective immune mechanisms.
Conclusions/Significance: These results suggest that presenting M2 on VLPs in a membrane-anchored form is a promising
approach for developing broadly cross protective influenza vaccines.
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Introduction
Vaccination is the most effective measure to control influenza.
Current influenza vaccines are based primarily on antibody
responses against the viral glycoprotein hemagglutinin (HA). HA-
specific antibodies neutralize viral infectivity and protect against
infection, which is the principle protective correlate of available
human influenza vaccines. A limitation of current vaccines is that
the major vaccine targets, the antigenic regions of HA, are highly
susceptible to continuous mutation in circulating epidemic virus
strains [1,2]. The high mutation rate of the viral genome and the
selection of mutants in the human host population result in
antigenic drift from the previous circulating strains [3]. In some
cases, novel pandemic strains can occur by reassortment of genes
between animal and human viruses [4]. The emergence of the
2009 pandemic H1N1 virus is a good example of the generation of
a new strain by triple reassortments with distinct antigenic
properties different from the circulating seasonal influenza viruses
[5,6]. While antibodies to HA provide potent virus strain-specific
protection, the vaccine formulations need to be evaluated on a
yearly basis to match the current circulating strains. The
development of a vaccine that can confer cross protection against
different influenza variants and subtypes is highly desirable, and
may limit the need for annual vaccination.
In contrast to HA, the influenza A M2 protein has a highly
conserved extracellular domain of 23 amino acids (M2e). However,
due to its small size and low immunogenicity, previous studies have
focused on M2e peptide fusion constructs using a variety of carrier
molecules: hepatitis B virus core [7–9], human papilloma virus L
protein [10], keyhole limpet hemocyanin [11], bacterial outer
membrane complex [8,12], liposome [13], and flagellin [14]. M2
vaccines based on M2e fusion carriers or DNA – recombinant
vector combination could provide cross protection against lethal
infection with different strains [8,11,13,15]. These studies suggested
that M2e antibody played an important role in providing
protection. However, previous studies on M2e conjugate vaccines
used potent adjuvants such as cholera toxins or heat labile
endotoxins’ derivatives, saponin QS21, Freund’s adjuvants, or
bacterial protein conjugates [8,9,12,14,16,17]. Such adjuvants that
nonspecifically elicit host responses including inflammation are
potentially adverse and unwarranted in developing a widely
applicable prophylactic influenza vaccine. More over, the longevity
and breadth of cross protection mediated by M2 immunity remain
largely unknown.
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Influenza virus-like particles (VLPs) containing HA and/or
neuraminidase (NA) on their surfaces in a membrane-anchored
form have been demonstrated to provide effective protection
suggesting a promising vaccine modality (reviewed in [18]). The
M2 protein is expressed as a tetrameric protein in a membrane
anchored form [19,20]. Therefore, it was likely that M2 would be
incorporated into VLPs in a native conformation during the
budding process on the cell surface. In this study, we investigated
the generation of VLPs containing the wild type M2 protein as
well as their immunogenicity, long-term cross-protective efficacy,
and the breadth of cross protection against heterologous and
heterosubtypic influenza strains even with a different M2e
sequence. In addition, the potential protective mechanisms of
immune responses to the M2 antigen are investigated and
discussed.
Results
Preparation of VLPs containing the A/WSN M2 protein
To investigate the role of M2 in inducing cross protection
against heterologous viruses, we produced influenza VLPs
containing the wild type M2 protein derived from influenza A/
WSN/33 virus (H1N1) (M2 VLPs). M2 VLPs were produced in
insect cells coinfected with recombinant baculoviruses (rBVs)
expressing M1 and M2, purified using sucrose gradient ultracen-
trifugation, and characterized by western blot using anti-M2
monoclonal antibody 14C2 [21]. The amount Of M2 protein
incorporated into VLPs was estimated to be approximately 1% of
the total protein (Fig. 1A). M2 VLPs produced in insect cells were
examined by transmission electron microscopy after negative
staining of VLPs (Fig. 1B). Spherical particles similar to the size of
virus were observed. Control M1 VLPs showed similar morphol-
ogy as M2 VLPs (not shown).
M2 VLPs induce M2-specific and broadly cross-reactive
antibody responses
To determine the immunogenicity of influenza VLPs containing
M2, a group of mice (6 BALB/c mice per group) was immunized
intranasally with VLPs containing M2 (20 mg total proteins) once or
twice at weeks 0 and 4. Levels of M2-specific IgG antibodies were
determined at 4 weeks after priming or at 4 weeks and 7 months
after boost immunizations by ELISA using the M2 ectodomain
peptide as a coating antigen (Fig. 2A). M2 specific antibodies were
detected in the M2 VLP immunized group (M2VLP) at significant
levels after priming with M2 VLPs. A control group of mice that was
immunized with M1 VLPs not containing M2 did not show an M2
specific antibody response (Mock). After boost immunization, levels
of antibodies specific to M2 were increased by over 2 fold (Fig. 2A).
M2 immune sera showed binding reactivity to M2 expressed on the
cell surfaces (Fig. 2B), indicating that M2 antibodies recognize the
native form of M2. This result is consistent with those observed by
immunization with the tetrameric ectodomain of M2 GCN4
conjugate vaccines [22]. Low but detectable levels of antibodies to
an M1 peptide pool antigen were observed in the M1 only VLP
group (Fig. 2C), which were similar to the M2 VLP group.
Therefore, these results indicate that vaccination with M2 VLPs can
induce M2 specific antibody responses that are long lived for over 8
months.
Since M2 is a protein which is conserved among various
influenza A strains, we tested whether M2 VLP immune sera
would be cross reactive with different influenza A virus subtypes.
Immune sera collected from mice boosted with M2 VLPs showed
significant levels of antibodies cross reactivities to influenza H1N1
(A/PR/8/34) as well as the heterosubtypic H3N2 A/Philippines/
82 virus (Fig. 2D). Importantly, M2 VLP immune sera also showed
significant levels of cross reactivity to an H5N1 virus (A/Vietnam/
1203/04) (Fig. 2D) and a 2009 H1N1 virus (A/California/4/2009)
(not shown) which have an M2 protein with different amino acid
sequences compared to the M2 protein (A/WSN/33) used for
vaccination (Table 1). In contrast, antibodies cross-reactive to
influenza B/Victoria were not observed in the M2 VLP immune
sera (Fig. 2D), indicating that M2 VLP vaccination induce cross-
reactive antibodies to the influenza A but not B type virus. To
determine the antigenic specificity, purified hemagglutinin (HA)
derived from A/PR/8/34 or A/Vietnam/1203/2004 was used as
an ELISA coating antigen. We found that there was no significant
reactivity to HA in M2 VLP immune sera (data not shown),
indicating that cross reactivity to different influenza viruses is likely
to be specific to M2 independent of HA subtype. When we
determined IgG1 and IgG2a isotype antibodies specific to M2
peptide antigen, IgG2a was found to be predominant after boost
immunization (Fig. 2E). Therefore, these results suggest that M2
VLPs are immunogenic and capable of inducing antibodies cross-
reactive to influenza A virions independent of HA subtype and in
the absence of adjuvant.
M2 VLPs provide protection against both H1N1 and
H3N2 viruses
To determine the ability of M2 VLPs to confer cross protection
against heterologous lethal challenge infection, groups of mice
intranasally immunized with M1/M2 VLPs (M2 VLPs) or M1
VLPs without M2 (Mock) were challenged with a lethal dose (3
LD50) of heterologous H1N1 A/PR/8/34 virus or heterosubtypic
H3N2 A/Philippines/82 virus at 4 weeks after vaccination (Fig. 3).
Figure 1. Characterization of influenza M2 VLP. (A) Western blotting of M2 VLP and recombinant M2e protein. M2 VLP (Lane 1; 0.5ug total
protein) and recombinant M2e protein (Lane 2, 3, 4; 15, 30 60 ng respectively) were loaded and detected by western blotting using mouse anti-M2e
monoclonal antibody (14C2). Amount of M2e protein incorporated in M2 VLP was calculated by spot densitometry analysis using serial diluted rM2e
protein as a standard. (B) Negative staining electron microscopy of influenza M2 VLP (bar = 100 nm).
doi:10.1371/journal.pone.0014538.g001
Cross Protection by M2 VLPs
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e14538
The body weight changes and survival rates were monitored
following challenge infection. All mock controls lost over 25% in
body weight and had to be euthanized (Fig. 3A). The mice that
received a single dose of M2 VLPs showed approximately 20%
body weight loss resulting in a survival rate of 25%. In contrast,
the mice that received prime boost immunizations with M2 VLPs
were 100% protected against lethal infection with A/PR8 virus
(Figs. 3A, B). These mice showed a loss of approximately 18% in
body weight at day 7 post challenge and then recovered to the
normal body weight. Similar to lethal challenge infection with A/
PR8 virus, the prime-boost immunized mice were also completely
protected against lethal challenge with A/Philippines virus and
showed a transient loss of 10% in body weight (Figs. 3C, D). These
results demonstrate that M2 VLP vaccination can provide
protection against lethal infection with either H1N1 A/PR8 or
H3N2 A/Philippines virus despite some accompanying morbidity
as shown by body weight loss.
M2 VLPs induce mucosal IgA antibodies and lower lung
viral titers
Mucosal immunity is important for conferring cross protection.
We therefore determined M2 specific IgA antibody responses in
various mucosal tissues after vaccination (Fig. 4A). Significant
levels of IgA antibody responses were observed in bronchoalveolar
lavage fluid (BALF) but not in nasal wash and lung samples
(Fig. 4A). Induction of mucosal IgA antibodies after vaccination is
consistent with results reported using intranasal vaccination with
M2 DNA and/or recombinant adenovirus vector vaccines [23,24].
Interestingly, a rapid increase in lung IgA antibodies specific to
M2 peptide was observed in the M2 VLP-immunized group but
not in the mock control group at day 4 after challenge compared
to that before challenge (Fig. 4B). Also, moderate levels of IgA
antibody responses were detected in nasal wash after challenge
(Fig. 4B). To better assess heterosubtypic cross protective efficacy
against A/Philippines/82 (H3N2), lung viral titers were deter-
mined at day 4 after challenge. The group of mice intranasally
immunized with M2 VLPs, which showed 100% protection
against A/Philippines/82, had 4 fold lower lung viral titers
compared to that in the mock control group (Fig. 4C). Therefore,
it is likely that M2 specific immune responses including IgA
antibodies in BALF and lungs can effectively contribute to
controlling heterosubtypic virus replication.
Figure 2. Antibody responses after M2 VLP vaccination. Groups of mice (n = 9) were intranasally immunized with 20 mg of M2 VLPs (M2VLP) or
M1 only VLPs without M2 (Mock) two times at weeks 0 and 4. Serum samples were taken 4 weeks after priming (4wks Prime) and at 4 weeks and 7
months after boost immunization (4wks Boost, 7mts Boost). The IgG antibody levels against M2e peptide (A), M2 expressed on cell surfaces (B), M1
peptides (C), and virus coated plates (D) were determined by ELISA and presented as optical density values read at 450nm (1006diluted sera). IgG1
and IgG2a isotype titers (E) against M2e peptide were determined by ELISA. Values mean average6S.D. of 1:100 diluted serum samples. The asterisk
indicates a significant difference between M2VLP and Mock groups, ** p,0.01; * p,0.05.
doi:10.1371/journal.pone.0014538.g002
Table 1. M2e amino acid sequence of influenza A viruses.
Viral strains M2e amino acid sequence
A/WSN/33 (H1N1) MSLLTEVETP IRNEWGCRCN DSSD
A/Puerto Rico/8/34 (H1N1)1 ------------------- -------------------- G------
A/Philippines/82 (H3N2) ------------------- --------------------- ---------
A/California/4/09 (2009 H1N1)2 ------------------- T--S-----E--------S ---------
A/Vietnam/1203/04 (H5N1)3 ------------------- T-------- E------- S ----------
Genebank Accession numbers:
11NP_040979.2;
2FJ969513.1;
3ABF01919.1.
doi:10.1371/journal.pone.0014538.t001
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M2 VLPs induce M2-specific T cell responses
T cell responses are known to contribute to broadening cross
protective immunity. After in vitro stimulation of cells with the M2
specific peptide, cytokine producing cell spots were measured as an
indicator of T cell responses (Fig. 5). Intranasal vaccination with M2
VLPs induced IL-4 secreting cells in spleens but not in lung and BAL
samples (Fig. 5A–5C). IFN-c secreting cells were not detected after
vaccination. To determine recall immune responses of M2-specific T
cells, spleen cells were collected at day 4 after challenge from mice 4
weeks post vaccination with M2 VLPs. Significant levels of IFN-c
Figure 3. Protection against heterologous lethal challenge. (A–B) Groups of vaccinated mice and a mock control were intranasally challenged
with a lethal dose (36LD50) of A/PR/8/34 (H1N1) influenza virus at 4 weeks after prime (n = 4) or boost (n = 9) vaccination. Body weight changes (A)
and survival rates (B) were recorded for 14 days. M2VLP/single, one time immunization with M2 VLPs, M2VLP/boost, prime-boost immunizations with
M2 VLPs, Mock: prime-boost immunizations with M1 only VLPs without M2. (C–D) A lethal dose (36LD50) of A/Philippines/82 (H3N2) influenza virus
was used to challenge the mice vaccinated with two doses of M2 VLPs. Body weight changes (C) and survival rates (D) were recorded daily (n = 5 mice
out of 9). Similar body weight changes and 100% protection were reproducible in duplicate experiments.
doi:10.1371/journal.pone.0014538.g003
Figure 4. M2 VLP vaccination induces mucosal IgA antibodies and lowers lung viral replication. Nasal wash, BALF, and lung samples
were collected from individual mice before challenge (A) and at day 4 post challenge (B) with A/Philippines/82 (H3N2) virus (n = 6) 4 weeks post boost
vaccination. Nasal wash (26diluted), BALF (26diluted), and lung homogenates (46diluted) were used for determination of IgA antibody responses
specific to M2 peptide (A–B). Lung virus titers (C) were determined by using a plaque assay. The asterisk indicates a significant difference between
M2VLP and Mock groups, * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0014538.g004
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secreting cells were observed in spleens although their levels were
lower than those of IL-4 secreting cells (Fig. 5D). Interestingly, spot
numbers of IFN-c secreting cells were significantly higher in lungs
and BAL samples after challenge than those of IL-4 (Fig. 5E–5F).
The mock control group immunized with VLPs without M2 showed
background levels similar to media only without M2 peptide
stimulation. These results provide evidence that M2 VLP immuni-
zation can induce M2 specific IL-4 secreting T cell responses in
spleens and IFN-c secreting recall T cell responses in mucosal tissues.
M2 VLP vaccination induces long-lasting protective
immunity
The longevity of protective immunity after vaccination with
conjugate M2e vaccines has not been previously reported. To
determine the longevity of protective immunity induced by M2
VLP vaccination, groups of mice that were intranasally immu-
nized with M2 VLPs were challenged with A/PR/8/34 virus
(Figs. 6A, B) or A/Philippines/82 (Figs. 6C, D) at 6 and 7 months
after boost vaccination respectively. Mice that were intranasally
immunized with M2 VLPs (20 mg total protein) using a prime
boost regimen were 100% protected against lethal challenge
infection with A/PR/8/34. Also, a group of mice that was
intranasally immunized twice with a lower dose of M2 VLPs
(10 mg) was 100% protected against a lethal challenge with H3N2
A/Philippines virus These results show that M2 VLP vaccines can
confer long-lasting protection against lethal infection.
M2 VLP immune serum contributes to protective
immunity
To better understand the protective role of anti-M2 immune
sera, we tested the capability of M2 immune sera to provide
protection in naı¨ve mice when infected with a lethal challenge.
Mixtures of a lethal dose of A/Philippines/82 virus (H3N2) and
M2 immune or naı¨ve sera were used to intranasally infect naı¨ve
mice. This method is a sensitive and previously well established
assay to assess the protective role of polyclonal immune sera [25–
27]. Naı¨ve mice that were infected with a mixture of virus and
mock immune sera showed severe body weight loss reaching to
below 75% of original weights by day 10 post-infection and all had
to be euthanized (Fig. 7). In contrast, M2 immune sera provided
complete protection to naı¨ve mice that were infected with a lethal
dose of A/Philippines/82 virus. Therefore, these results suggest
that anti-M2 immune sera play an important role in providing
heterosubtypic cross protection.
Next, we studied the potential roles of lung airway dendritic and
macrophage cells in conferring anti-M2 antibody-mediated cross
protection against the antigenically distinct 2009 pandemic H1N1
virus (Fig. 8). Previous studies demonstrated the selective depletion
of lung dendritic and macrophage cells by intranasal or
intratracheal administration with clodronate-liposomes [28,29].
Similarly, we sought to selectively deplete lung dendritic and
macrophage cells by intranasal administration of clodronate-
liposomes. As shown in Fig. 8A, CD11c+ DC and CD11b+
macrophage cells were found to be depleted by 55% and 62%
respectively after clodronate-liposome treatment, which is consis-
tent with the depletion efficiency reported in a previous study [29].
Naı¨ve mice with or without clodronate-liposome treatment were
infected with a lethal dose of infectious virus mixed with M2
immune sera (Fig. 8B, 8C). M2 VLP immune sera could also
transfer cross protection to naı¨ve mice from a lethal infection with
a 2009 H1N1 virus (Fig. 8), as was seen with H3N2 A/
Philippines/82 virus (Fig. 7). Regardless of treatment with
clodronate-liposomes (Mock, Mock/DC(-)), mock immune sera
Figure 5. Cellular immune responses. The cellular immune responses were assessed with splenocytes isolated from mice 4 weeks boost
immunization with M2 VLPs or M1 only VLPs without M2 (Mock) before challenge (A–C) and at 4 day post challenge (D–F) with A/Philippines/82 virus
(n = 6). Cells from spleen (A, D), lung (B, E), and BAL (C, F) were stimulated with M2 peptides for 2 days and cytokine forming cell spots were
determined by ELISPOT assay. The asterisk indicates a significant difference between M2VLP and Mock groups, * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0014538.g005
Cross Protection by M2 VLPs
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did not provide any protection against the 2009 pandemic H1N1
virus. Importantly, naı¨ve mice that received clodronate-liposome
treatment were not protected against the 2009 H1N1 virus mixed
with M2 VLP immune sera, and all mice in this group died. These
results indicate that dendritic and macrophage cells might be
important for conferring M2 immune serum-mediated cross
protection.
Discussion
M2 vaccines in a membrane-anchored form on VLPs have not
been previously tested for their cross protective efficacy. Results in
this study demonstrate that M2 VLP vaccination can induce M2
specific antibody responses cross reactive to heterologous viruses,
T cell responses, and long-lasting protective immunity against
Figure 6. Long-term protection against heterologous lethal challenge by M2 VLP vaccination. (A–B) At six months after prime-boost
immunizations with M2 VLPs, mice (n = 5) were challenged with a lethal dose (36LD50) of A/PR/8/34 (H1N1) influenza virus. A) Body weight changes,
B) Survival rates. (C–D) Mice (n = 5) that were intranasally immunized with M2 VLPs 7 months earlier were challenged with A/Philippines/82 (H3N2)
virus. Body weight changes (C) and survival rates (D) are shown.
doi:10.1371/journal.pone.0014538.g006
Figure 7. Protective efficacy against influenza A H3N2 virus of M2 VLP immune sera. Immune sera collected from M2 VLP vaccinated mice
at 4 weeks after boost vaccination were incubated with a lethal dose of A/Philippines/82 (H3N2) influenza virus at room temperature for 30 min.
Groups of mice (n = 4) were intranasally challenged with a lethal infectious dose mixed with M2 immune sera (M2VLP) or Mock sera. Body weight (A)
and survival rate (B) were monitored for 14 days. 100% protection and similar body weight changes were obtained from sera of the M2VLP group in
duplicate experiments.
doi:10.1371/journal.pone.0014538.g007
Cross Protection by M2 VLPs
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lethal challenges with heterologous or heterosubtypic viruses.
Influenza M2 vaccine approaches based on VLPs are desirable
since these VLPs were found to be immunogenic in the absence of
adjuvant. In contrast, conjugate-based M2 vaccines required the
use of adjuvants that would be problematic for human use
[8,9,12,14,16,17]. Therefore, developing influenza M2 vaccines
based on VLPs is significant since VLPs containing M2 can be
easily produced, and are safe and practical for public health use.
Previous studies have focused on chemical or genetic fusion
constructs of the M2 extracellular peptide domain (M2e), which
were shown to provide partial or complete protection against
lethal infection in animal models (reviewed in [30]). M2 immunity
and protection were reported by vaccination of animals with M2e
peptide in chemical or genetic conjugates (carrier molecules or
virus particles) [7–9,12,14,16,17,22,31], or DNA vaccines and/or
combination of DNA and recombinant or live influenza vaccines
[11,23,24,32]. These conjugate or genetic M2e vaccines even
together with potent adjuvants were not completely protective
since vaccinated animals showed disease symptoms visible by
weight loss. Chemical or genetic conjugation of M2e would not
represent M2 in its tetrameric membrane-anchored native form.
As a vaccine antigen, use of the wild type M2 protein would be
advantageous since it is likely to present M2 in a native
conformation. In the present study, influenza M2 VLPs were
produced by a budding process in insect cells expressing influenza
M1 and M2. Consistent with the results in previous studies
reporting weak protective immunity to M2, vaccination with M2
VLPs in the absence of adjuvant did not prevent body weight
losses in protected mice. Approaches to increase the immunoge-
nicity of M2 VLPs include chimeric or multi-components VLPs
incorporating HA or molecular adjuvants into M2 VLPs. We have
demonstrated enhanced immunogenicity of chimeric VLPs
containing granulocyte-macrophage colony stimulating factor
[33], which could further improve cross protective efficacy possibly
preventing weight loss.
Our study demonstrated that M2 VLP vaccination induces
antibodies binding to the M2 extracellular peptide, the native form
of M2 expressed on cell surfaces, as well as to purified virions
regardless of HA subtype. It is likely that M2 specific antibodies
induced by M2 VLP vaccination recognize the native form of M2
Figure 8. Effects of clodronate-liposomes on protective efficacy against 2009 H1N1 virus by M2 immune sera. (A) A representative flow
cytometry profile of DC and macrophage cell gates. Naive mice were intranasally treated with PBS (i) or clodronate-liposome (ii), and DC cells
(CD11b+CD11c+) and macrophage cells (CD11b+CD11c2) in lungs were analyzed by flow cytometry. (B–C) Roles of DC/macrophage cells in the cross
protection mediated by M2 immune sera. (B) Body weight changes against A/Califonia/04/2009. (C) Survival rates against A/Califonia/04/2009. To
deplete dendritic cells (DC) and alveolar macrophages, groups of naı¨ve mice (n = 4) were intranasally instilled with clodronate-liposomes 4 hrs prior to
lethal infection. A lethal dose of A/Califonia/04/2009 (H1N1) influenza virus was incubated with sera collected from M2 VLP vaccinated mice at 4
weeks after boost immunization and used to infect naı¨ve mice with or without clodronate-liposome pretreatment. M2VLP: M2VLP immune sera in
mice without clodronate-liposome; M2VLP/DC(-):M2VLP immune sera in mice with clodronate-liposome, Mock: Mock immune sera in mice without
clodronate-liposome; Mock/DC(-):Mock immune sera in mice with clodronate-liposome.
doi:10.1371/journal.pone.0014538.g008
Cross Protection by M2 VLPs
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on virions. It was reported that vaccination with recombinant M2e
fused to the oligomerization domain of GCN4 induced antibodies
binding to cell surfaces expressing M2 [22]. Although anti-M2
antibodies may not directly neutralize the virus [34], influenza
viruses bound to M2 antibodies might be preferably recognized
and removed by opsonophagocytosis by macrophages. In support
of this idea, it was demonstrated that M2 monoclonal antibodies
which preferentially bind to M2 multimeric forms but not the
monomeric form were protective, and that this was independent of
natural killer cell mediated effector functions [35]. In a previous
study, M2 antibodies induced by M2e conjugate vaccination did
not efficiently bind to the free virus particles, and natural killer
cell-dependent elimination of infected cells was shown to
contribute to the relatively weak protection observed [34],
suggesting an alternative mechanism for M2 antibody mediated
protection.
IgG2a antibody is an isotype known to interact efficiently with
complement and Fc receptors [36–39]. We found that IgG2a was
the predominant isotype induced by M2 VLP vaccination and that
mice immunized with M2 VLPs showed reduced lung viral titers.
Huber et al. demonstrated that non-neutralizing anti-influenza
humoral immunity was dependent on opsonophagocytosis of
influenza virions by macrophages [36,40–42]. Therefore, we
suggest that induction of virus-binding IgG2a antibodies by M2
VLP vaccination contributes to viral clearance, possibly via
opsonizing virus by macrophages and dendritic cells. We found
that M2 VLP immune sera were able to confer protection against
lethal infection in naı¨ve mice, indicating that anti-M2 antibodies
play an important role in providing protection against lethal
infection. Furthermore, we obtained evidence that this protection
by M2 immune sera might be mediated by dendritic and
macrophage cells as shown by depletion experiments using
clodronate-liposomes. A possible explanation is that anti-M2
antibodies may by itself be too weak to protect the mice and may
just contribute to protection. At the same time, dendritic cells and
macrophages which are not by themselves sufficient for protection
may contribute to innate and early adaptive immune responses
triggered by challenge infection and enhancing the virus uptake of
antibody bound particles via antigen presenting cells. Therefore,
the combination of those responses and the anti-M2 antibodies
may protect the mice. In support of this hypothesis, we observed
rapid increases in levels of lung IgA antibodies and IFN-c secreting
cell responses at an early time post challenge. Further studies are
ongoing to better understand the M2-immune mediated protec-
tion mechanism.
Our results demonstrated that M2 VLP vaccination was able to
induce long-lasting M2e specific antibodies and to provide
protection against lethal challenge even at 7 months after
vaccination. Thus, it is possible that long-lived M2-specific
antibody responses might contribute to conferring long-term
protective immunity since antibody-mediated immunity is usually
long-lived and most successful antiviral vaccines are based on the
induction of protective antibody responses [43–45]. Also, in a
previous study using NP/M2 DNA prime - NP/M2 recombinant
adenovirus vector boost regimen, intranasal immunization in-
duced long-lived NP/M2 specific IgG and IgA antibodies in sera
and mucosal sites [24]. In addition, M2 immunity might be
affected depending on the genetic background of mouse species
[46], suggesting that M2 alone immunity observed in BALB/c
mice might not be well translated to heterogeneous human
population. The influenza M1 component in VLPs and/or
combination vaccination with conserved NP might provide better
coverage of human leukocyte antigen haplotypes in the genetically
diverse human population [24,47]. Alternatively, incorporating
immunostimulatory molecules into VLPs might be an approach
for inducing M2 immunity independent of CD4 T cell help [48].
Therefore, further studies on M2 vaccination are needed to
improve cross protective immunity and to prevent morbidity as
shown by body weight loss.
In summary, we observed that M2 VLP vaccination induced in
the absence of adjuvant protective immunity against a H1N1 virus
(A/PR/8/34) as well as an H3N2 subtype virus (A/Philippines/
82). Also, M2 VLP immune sera can provide protection to naı¨ve
mice against the 2009 pandemic H1N1 virus (A/California/4/
2009) that contains differences in the M2 protein sequence
(Table 1). Cross protection was observed up to 7 months post
vaccination, suggesting that M2 VLP based protective immunity is
long-lasting. Therefore, we believe that M2 VLP vaccines would
be safe, convenient, and practical for public health use. Further
studies are needed to develop improved vaccines based on
influenza M2 VLPs, a highly conserved target which can be
applied as a universal vaccine against influenza A viruses.
Materials and Methods
Cells, Viruses, and Reagents
Spodoptera frugiperda sf9 insect cells (ATCC, CRL-1711) were
maintained in SF900-II serum free medium (Invitrogen, Carlsbad,
CA) at 27uC and used for production of recombinant baculo-
viruses (rBVs) and VLPs. Madin-Darby canine kidney (MDCK)
cells used for viral titration were purchased from ATCC and
cultured in Dulbecco’s Modification of Eagle’s Medium (DMEM)
with 10% fetal bovine serum [26]. Influenza A viruses, A/
California/4/2009 (2009 pandemic H1N1 virus) kindly provided
by Dr. Richard Webby, mouse adapted A/Philippines/2/1982
(H3N2) and A/PR/8/34 (H1N1) generously provided by Dr.
Huan Nguyen, and influenza B virus (B/Victoria/2/87, ATCC)
were propagated in the allantoic cavity of 11 day-old embryonated
chicken eggs for 48 hrs at 37uC. Harvested allantoic fluid was
clarified by centrifugation (3000 rpm, 30min) and kept at 280uC.
Inactivated A/VietNam/1203/04 (H5N1) influenza virus and
purified H5 HA soluble protein were obtained from the NIH
Biodefense and Emerging Infections Research Resources Repos-
itory (NIAID, NIH). A recombinant H1 HA protein derived from
the A/PR8 strain was expressed using the baculovirus expression
system and purified using a His-Tag affinity column. Influenza
virus M2e (17 amino acids 2 to 18, N-SLLTEVETPIRNEWGCR)
was synthesized at the Biochemical Core Facility in Emory
University.
Preparation and characterization of M2 VLPs
A full length M2 cDNA was generated by RT-PCR from total
RNA isolated from MDCK cells infected with A/WSN/33
influenza virus (H1N1) and cloned into the pFastBac vector
plasmid which was subsequently used to make recombinant
Bacmid baculovirus DNAs using DH10Bac competent cells
(rAcNPV, Invitrogen, Carlsbad, CA). A recombinant baculovirus
(rBV) expressing influenza M2 protein was generated by
transfection of sf9 insect cells according to the manufacturer’s
instruction. To produce influenza VLPs containing the wild type
M2 protein (M2 VLPs), rBVs expressing M1 and M2 protein were
co-infected into sf9 insect cells at multiplication of infection of 3.
At 2 days post-infection, the infected cell culture supernatants were
clarified by centrifugation (3000 rpm, 30 min) and then were
concentrated by a QuixStand hollow fiber based ultrafiltration
system (GE Healthcare, Piscataway, NJ). Influenza M2 VLPs were
purified by sucrose gradient ultracentrifugation with layers of 20%
and 60% (wt/vol) as previously described [26]. Influenza A virus
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M2 monoclonal antibody 14C2 (Abcam Inc., Cambridge, MA)
was used for detection of M2 protein by western blotting of M2
VLPs. To quantify the amount of M2 incorporated into VLPs,
His-tag affinity purified M2 protein produced by the rBV
expression system was used as a standard. Western blots were
analyzed by densitometer scanning using Alphaview software
(Alpha Innotech, Santa Clara, CA). The morphology of VLPs was
examined by electron microscopy at the Integrated Electron
Microscopy Core Facility of Emory University as described [26].
Immunization and challenge
For animal experiments, 6–8 weeks old female BALB/c mice
(Harlan Laboratories, Indianapolis, IN) were immunized intrana-
sally with 20 mg of M2 VLPs (M2VLP) or M1 only VLPs without
M2 (Mock) with a single or two doses at 4 weeks interval. Four
weeks after prime or boost immunization, mice were challenged
with a lethal dose of A/PR/8/34 (3650% mouse lethal dose (3
LD50) or A/Philippines/82 influenza virus (3 LD50). To determine
the long-term protective efficacy, additional groups of mice (n = 9)
were immunized intranasally with 10 or 20 mg of M2 VLPs two
times (weeks 0 and 4) and challenged with a lethal dose (3 LD50) of
A/PR/8/34 (H1N1) or A/Philippines/82 influenza virus 6 or 7
months post vaccination respectively. Mice were monitored daily
to record weight changes and mortality (25% loss in body weight
as the Institutional Animal Care and Use Committee (IACUC)
endpoint). Full details of this study and all animal experiments
presented in this manuscript were approved by the Emory
University IACUC review board (approval number 179-2008
IACUC) and conducted under the guidelines of the Emory
University IACUC. Emory IACUC operates under the federal
Animal Welfare Law (administered by the USDA) and regulations
of the Department of Health and Human Services.
Determination of serum antibody responses specific to
M2
Blood samples were collected before and at 3 weeks after each
immunization and stored 220uC until analysis. M2 specific serum
antibody responses were determined by ELISA using synthetic
M2e peptide or inactivated purified virions (2 mg/ml) as a coating
antigen as previously described [26,49]. Briefly, HRP-conjugated
goat anti-mouse IgG, IgG1 and IgG2a were used as secondary
antibodies to determine total IgG and isotype antibodies. The
substrate O-phenylenediamine (OPD) (Zymed, San Francisco,
Calif.) in citrate-phosphate buffer (pH 5.0) containing 0.03%
H2O2 (Sigma) was used to develop color. The optical density at
450 nm was read using an ELISA reader.
M2 expressing MDCK cells [50] were maintained in DMEM
media with 7.5 mg/ml of puromycin (Invitrogen, Carlsbad, CA),
5 mM of amantadine (Sigma, St. Louis, MO) and 10% FBS
(Invitrogen, Carlsbad, CA) at 37uC in air/CO2. Confluent M2
expressing MDCK monolayer cells were fixed by 0.05%
glutaraldehyde or 10% buffered formalin (Sigma, St. Louis,
MO) for 30 min at room temperature and used to determine
antibody levels binding to M2 expressed on cell surfaces by ELISA
as described [22]. M1 specific antibody responses were determined
using the M1 protein peptide pool (2 mg/ml) derived from
influenza A/New York/348/2003 (H1N1) virus (BEI resources,
Manassas, VA).
Nasal wash and BAL samples preparation
Nasal wash was collected by flushing through the trachea to
nose with 500 ml of PBS for 5 individual mice and stored at
280uC until analysis. Bronchoalveolar lavage (BAL) fluid and cells
were obtained by infusing 1 ml of PBS using a 25-gauge catheter
into the lungs via the trachea. BAL cells were recovered and
pooled from BAL fluid by centrifugation (1200 rpm, 5min) for the
determination of cytokine secretion.
Cross protective efficacy test of immune sera and effects
of clodronate-liposomes
To test cross protective efficacy of immune sera in vivo, serum
samples from immunized and mock control mice were pre-
incubated with a lethal dose of influenza virus at room
temperature for 30min as described [25]. A mixture of a lethal
infectious dose of A/Philippines/82 (H3N2) or A/California/4/
2009 (H1N1) influenza virus (3 LD50) and sera was administered to
naive mice (n = 4 BALB/c), and body weight changes and survival
rates were monitored daily. Liposome-encapsulated clodronate
and control liposomes containing PBS only were prepared as
previously described [51]. Four hrs prior to infection with virus-
serum mixture, some groups of naı¨ve mice (n = 6 BALB/c) were
intranasally treated with clodronate-liposomes to deplete dendritic
and macrophage cells as described [28,29,52]. Clodronate was a
kind gift of Roche Diagnostics GmbH, Mannheim, Germany.
Flow cytometry
The depletion efficacy of lung macrophage and DC cells was
determined by flow cytometry as described [29]. Briefly, the
homogenized lung tissues were incubated with DNase I (100 ug
per ml, Sigma) and type IV collagenase (2 mg/ml, Worthington)
for 30 min at 37uC, and then passed through a cell strainer
(40 mm, BD, Franklin Lakes, NJ). The single-cell suspensions were
stained with fluorescence conjugated antibodies specific to cell
phenotypes (CD11c, CD11b). Lung macrophage and DC cells
were gated according to their sizes and granularity defined in the
forward light scatter (FSC) and side light scatter (SSC) plot and
sorted based on their CD11b/CD11c profiles. Cell acquisition was
performed with a dual-laser flow cytometer (LSR-II, BD
Biosciences, Mountain View, CA ) and the data were analyzed
using FlowJo software (Tree Star, INC., Ashland, OR).
Lung viral titers and immune responses
Lung tissues were isolated from mice (n = 4) sacrificed at day 4
post challenge with influenza A/Philippines/82 H3N2 virus after
4 weeks after boost vaccination. Lung extracts were prepared using
a mechanical tissue grinder with 1ml of PBS per each lung and
viral titers were determined using plaque assay in MDCK cells as
previously described [25,26].
Determination of T cell responses
Spleens were isolated from the same mice sacrificed at 4 day
post challenge and single cell suspensions were prepared as
described [53]. Interferon (IFN)- c and interleukin (IL)-4 secreting
cell spots were determined on Multi-screen 96 well plates
(Millipore, Billerica, MA) coated with cytokine specific capture
antibodies as described [53]. Briefly, 0.56106 spleen cells per well
were cultured with or without M2e peptide (10 mg/ml) as an
antigenic stimulator. After 36 h incubation, the number of IFN-c
or IL-4 secreting T cells was counted using an ImmunoSpot
ELISpot reader (Cellular Technology, Shaker Heights, OH.).
Statistical analysis
To determine the statistical significance, a two-tailed Student’s
t-test was used when comparing two different conditions. A p value
less than 0.05 was considered to be significant.
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